Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the disease is usually diagnosed at an advanced stage, i...
Main Authors: | Silvia Martin Lluesma, Anita Wolfer, Alexandre Harari, Lana E. Kandalaft |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-05-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | http://www.mdpi.com/2227-9059/4/2/10 |
Similar Items
-
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
by: Ananda Mookerjee, et al.
Published: (2019-01-01) -
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
by: Apostolos Sarivalasis, et al.
Published: (2019-11-01) -
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
by: Ananda Mookerjee, et al.
Published: (2018-05-01) -
Development of Therapeutic Vaccines for Ovarian Cancer
by: Stephanie Chow, et al.
Published: (2020-11-01) -
Dendritic Cell Vaccines in Ovarian Cancer
by: Xi Zhang, et al.
Published: (2021-01-01)